26358-75-8

Basic information

• Product Name: cholest-5-ene-1alpha,3beta-diol
• Synonyms: cholest-5-ene-1alpha,3beta-diol;Cholest-5-ene-1α,3β-diol
• CAS NO: 26358-75-8
• Molecular Formula: C₂₇H₄₆O₂
• Molecular Weight: 402.65294
• EINECS: 247-630-4
• Mol File: 26358-75-8.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 514°Cat760mmHg
• Flash Point: 214°C
• Appearance: /
• Density: 1.03g/cm³
• CAS DataBase Reference: cholest-5-ene-1alpha,3beta-diol(CAS DataBase Reference)
• NIST Chemistry Reference: cholest-5-ene-1alpha,3beta-diol(26358-75-8)
• EPA Substance Registry System: cholest-5-ene-1alpha,3beta-diol(26358-75-8)

Safety Data

• Hazardous Substances Data: 26358-75-8(Hazardous Substances Data)

Upstream product

• 66875-23-8 (20S)-1α,3β-Diacetoxy-20-methyl-5-pregnen-21-al 
• 35573-82-1 C₂₉H₄₈O₃ 
• 66875-22-7 (20S)-20-Methyl-5-pregnen-1α,3β,21-triol 
• 80164-10-9 (20S)-20-Methyl-1α,3β-bis<(tetrahydropyran-2-yl)oxy>-5-pregnen-21-ol-p-toluolsulfonat 
• 80188-98-3 1α,3β,25-Tris<(tetrahydropyran-2-yl)oxy>-5-cholesten-23-in 
• 66875-29-4 (20S)-(20-Methyl-5-pregnen-1α,3β,21-triol)-1,3-diacetat-21-p-toluolsulfonat 
• 66875-27-2 (20S)-20-Methyl-1α,3β-bis<(tetrahydropyran-2-yl)oxy>-5-pregnen-21-saeure-methylester 
• 81481-28-9 (20S)-(20-Methyl-1α,3β-bis<(tetrahydropyran-2-yl)oxy>-5-pregnen-21-ol)acetat 
• 80164-09-6 (20S)-(20-Methyl-5-pregnen-1α,3β,21-triol)-21-p-toluolsulfonat 
• 66875-28-3 (20S)-(20-Methyl-1α,3β-bis<(tetrahydropyran-2-yl)oxy>-5-pregnen-21-ol) 
• 66875-25-0 (20S)-1α,3β-Dihydroxy-20-methyl-5-pregnen-21-saeure-methylester 
• 81481-27-8 (20S)-(20-Methyl-5-pregnen-1α,3β,21-triol)-21-acetat 
• 66875-24-9 (20S)-1α,3β-Dihydroxy-20-methyl-5-pregnen-21-saeure 
• 66875-21-6 (20S)-(20-Methyl-5-pregnen-1α,3β,21-triol)-1α,3β-diacetat 

Downstream Products

• 53869-68-4 1α,3β-dibenzoyloxycholest-5-ene 
• 43217-89-6 1α,3β-dihydroxycholesta-5,7-diene 
• 41461-10-3 1α,3β-diacetoxycholesta-5,7-diene 
• 41294-56-8 1α-hydroxyvitamin D3 
• 35339-66-3 cholest-5-ene-1α,3β-diol 3β-acetate 
• 35339-68-5 cholest-5-ene-1α,3β-diol 1α,3β-diacetate 
• 35339-68-5 (5-Cholesten-1α,3β-diol)-diacetat 
• 35339-66-3 cholest-5-ene-1α,3β-diol 3-acetate 

Relevant articles and documents

A novel strategy for the synthesis of bromo-substituted cholestenone and its new application to a synthesis of 1α-hydroxycholesterol

A novel and efficient method was developed for the preparation of bromo-substituted cholestenone, including 6β-bromocholestenone and 2α,6β-dibromocholestenone. The key step in this synthesis is a very mild method for the transformation of 5α,6β-dibromocholesterol into the 6β-bromocholestenone by treatment with NaClO/NaBr/TEMPO, followed by dehydro-bromination with Et3N. Bromination at C-2 with NBS/BPO (benzoyl peroxide) gave the 2α,6β-dibromo cholestenone. This was used in a synthesis of 1α-hydroxycholesterol.

-

-

Studies in 1α-hydroxyl derivatives of vitamin D3. I. Syntheses of 1α-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3

-

Synthesis and evaluation of new 6-hydroximinosteroid analogs as cytotoxic agents

Taking into account the structural requirements for cytotoxicity, several new hydroximinosteroid derivatives have been prepared and evaluated for their cytotoxic activity against A-549, H116, PSN1, and T98G cultured tumor cell lines in order to obtain further information on the potential pharmacophoric core of this type of compound. The influence of the oxygenated position in the A ring, the presence of an additional oxygenated position at C-7 and C-16, and a fluorinated position at C-5 were considered in order to study the structure-activity relationships. The results reveal the importance of oxygenated positions in the A ring (e.g., 4,5-epoxide showed an IC50 value against HCT-116 under micromolar level) for an increase in cytotoxic activity in this type of compound. Furthermore, they showed an important selectivity toward colon tumor line (HCT-116).

1-α-hydroxy vitamin D compounds and process for preparing same

The invention provides novel 1α-hydroxy vitamin D compounds and a method for their preparation from 1α-hydroxy-25-hydrogen cholesta-5,7-dienes by irradiation and isomerization techniques. The invention also includes the said 1α-hydroxy-25-hydrogen-cholesta-5,7-dienes and the corresponding cholest-5-enes. The new compounds may be obtained in a crystalline form substantially free from isomeric or other impurities arising from manufacture.